Thomas McFaden, MD
Family Medicine · Birmingham, ALNPI 1821319971
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $359 and has fallen 83.0% since, to $61 in 2025.
Across 82 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$235
- Novo Nordisk$167
- Amgen$120
- Lilly USA, LLC$115
- AstraZeneca$112
- Pfizer$81
- plus $342 from 14 others
What the payments were for
- Food & beverage$1,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $235 |
| Novo Nordisk | 10 | $167 |
| Amgen(2 entities) | 7 | $120 |
| Lilly USA, LLC | 8 | $115 |
| AstraZeneca | 8 | $112 |
| Pfizer | 5 | $81 |
| Sun Pharmaceutical Industries Inc. | 3 | $53 |
| GSK | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $28 |
| Merck | 2 | $24 |
| Boston Scientific | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Gilead | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$1,171 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $57,038 |
| FarxigaDapagliflozin Propanediol | 56 | $47,406 |
| RybelsusSemaglutide | 35 | $40,977 |
| JanuviaSitagliptin Phosphate | 39 | $36,626 |
| EliquisApixaban | 21 | $18,043 |
| MounjaroTirzepatide | 16 | $17,391 |
| XareltoRivaroxaban | 13 | $10,630 |
| LinzessLinaclotide | 14 | $10,046 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,910 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,736 |
| InvokanaCanagliflozin | 12 | $6,721 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $2,950 |
| Atorvastatin Calcium | 230 | $2,710 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 53 | $2,582 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $2,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $167 | $98,01586 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $112 | $54,14271 claims |
| MerckJanuvia | $24 | $36,62639 claims |
| PfizerEliquis | $81 | $18,04321 claims |
| Lilly USA, LLCMounjaro | $115 | $17,39116 claims |
| AbbVieLinzess | $235 | $10,04614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Birmingham
- Lashelle BarmoreBirmingham$486K
- Scott WeisbergBirmingham$38K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.